vTv Therapeutics Inc (VTVT)


Stock Price Forecast

Feb. 21, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading vTv Therapeutics Inc chart...

About the Company

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and inflammatory disorders, including psoriasis. vTv's development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), renal disease, and primary mitochondrial myopathy.

Employees

25

CEO

Stephen Holcombe

Exchange

NASDAQ

Website

www.vtvtherapeutics.com

$5M

Total Revenue

25

Employees

$47M

Market Capitalization

-3.25

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $VTVT News

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

5d ago, source:

Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund.Company's first ...

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

20d ago, source: Yahoo Finance

HIGH POINT, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399 ...

vTv Therapeutics Inc. Cl A

5d ago, source: Wall Street Journal

1 Day VTVT 6.30% DJIA -0.35% Russell 2K -1.96% Health Care/Life Sciences -0.13% ...

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

14d ago, source:

HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused ...

VTv Therapeutics: Q4 Earnings Snapshot

5d ago, source: The Washington Post

HIGH POINT, N.C. — HIGH POINT, N.C. — VTv Therapeutics Inc. (VTVT) on Wednesday reported a loss of $3.5 million in its fourth quarter. The High Point, North Carolina-based company said it had ...

vTv Therapeutics Inc Class A

18d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

vTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

5d ago, source:

Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund.Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...